A Phase 2 interventional study of Idasanutlin in Polycythemia Vera, sponsored by Hoffmann-La Roche. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-08.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
This is an open-label, single-arm study of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV). The study will include two phases: initial phase and expansion phase. The initial phase will assess the safety and efficacy of idasanutlin monotherapy in ruxolitinib naïve and ruxolitinib-resistant or intolerant patients, respectively. If the initial phase shows promising results for ruxolitinib-resistant or intolerant patients, an expansion phase will be opened to further characterize the efficacy of idasanutlin.
Exclusion Criteria:
Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
Drug: Idasanutlin
All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
Also known as: RO5503781, RG7388
Percentage of Ruxolitinib-Naïve Participants With Splenomegaly at Baseline Who Achieved Composite Response at Week 32
Composite response is defined as hematocrit (Hct) control without phlebotomy and ≥35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of ≥45% that was ≥3% higher than baseline level or a Hct of \>48%. One Cycle is 28 Days.
Time frame: Week 32
Percentage of Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline Who Achieved Hematocrit (Hct) Control Without Phlebotomy at Week 32
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
Time frame: Week 32
Percentage of All Ruxolitinib-Naïve Participants (Irrespective of Spleen Size) Who Achieved Hct Control Without Phlebotomy at Week 32
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
Time frame: Week 32
Percentage of All Ruxolitinib-Resistant or Intolerant Participants Who Achieved Hct Control Without Phlebotomy at Week 32
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
Time frame: From Baseline to Week 32 (Cycle 8 Day 28)
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Response at Week 32
Complete hematologic response requires all of the following: Hct control without phlebotomy; White blood cell (WBC) count ≤10 × 10\^9/Liter (L) at Week 32; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
Time frame: Week 32 (Cycle 8 Day 28)
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Remission at Cycle 11 Day 28
Complete hematologic remission requires all of the following: Hct control without phlebotomy between Weeks 32 and Cycle 11 Day 28; WBC count ≤10 × 10\^9/L at Cycle 11 Day 28; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
Time frame: Cycle 11 Day 28
Duration of Complete Hematologic Remission, With a Durable Responder Defined as a Participant in Remission at Week 32 and Cycle 11 Day 28
Complete hematologic remission requires all of the following: Hct control without phlebotomy between Week 32 (Cycle 8 Day 28) and Cycle 11 Day 28; WBC count ≤10 × 10\^9/L at Cycle 11 Day 28; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%
Time frame: Week 32 (Cycle 8 Day 28), Cycle 11 Day 28
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline by Response Per Modified European Leukemia Net (ELN) Criteria
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
Time frame: Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline by Response Per Modified ELN Criteria
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
Time frame: Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) by Response Per Modified ELN Criteria
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
Time frame: Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 are analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Number of Participants With a Durable Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Number of Participants With a Durable Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) With Durable Response Lasting at Least 12 Weeks From Week 32
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Number of Participants With a Duration Response, in All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) With Durable Response Lasting at Least 12 Weeks From Week 32
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Total Number of Participants With Adverse Events by Severity, Graded According to NCI CTCAE v4.0
An adverse event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. The adverse event severity grading scale for the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0) will be used for assessing adverse event severity. During the final analyses, the focus was on the Adverse Events of severity grades \>/=3 as shown below. The extensive listings of all grade AEs are available at request. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline to end of study (up to 2 years)
Percentage of Participants With Clinical Laboratory Abnormalities: Hematology Parameters.
Hematology parameter laboratory values falling outside the standard reference range were planned to be recorded as either high or low. There was no clinical laboratory abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
Time frame: Baseline to end of study (up to 2 years)
Percentage of Participants With Clinical Laboratory Abnormalities: Clinical Chemistry Parameters
Clinical chemistry parameter laboratory values falling outside the standard reference range were to be recorded as either high or low. There was no clinical chemistry abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
Time frame: Baseline to end of study (up to 2 years)
Percentage of Participants With Clinical Laboratory Abnormalities: Urinalysis Parameters
Urinalysis parameter laboratory values falling outside the standard reference range were planned to be recorded as either high or low. There was no clinical laboratory (urinalysis) abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
Time frame: Baseline to end of study (up to 2 years)
Change From Baseline in Electrocardiogram Parameters: PQ(PR), QRS, QT, QTcB, QTcF, and RR Durations
Single 12-lead ECGs was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Day 1, hours 4 and 6, Day 2 pre-dose and 24 Hour, Day 5 pre-dose, 4 and 6 Hour), Cycle 2 (Day 1 pre-dose only), Cycle 3 (Day 1 pre-dose, 4 and 6 Hour), Cycle 4 (Day 1 pre-dose and 4 Hour)
Change From Baseline in Heart Rate, as Measured by Electrocardiogram
Single 12-lead ECGs was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Day 1, hours 4 and 6, Day 2 pre-dose and 24 Hour, Day 5 pre-dose, 4 and 6 Hour), Cycle 2 (Day 1 pre-dose only), Cycle 3 (Day 1 pre-dose, 4 and 6 Hour), Cycle 4 (Day 1 pre-dose and 4 Hour)
Change From Baseline in Oral Temperature
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
Time frame: Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Change From Baseline in Pulse Rate
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Change From Baseline in Respiratory Rate
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Change From Baseline in Systolic Blood Pressure
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Change From Baseline in Diastolic Blood Pressure
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
Time frame: Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Eastern Cooperative Oncology Group (ECOG) Performance Status Over Time
The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction), 1=Symptomatic but completely ambulatory, 2=Symptomatic, \< 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, \> 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Only baseline data were collectable. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the planned end of study.
Time frame: Baseline
Percentage of Participants With Concomitant Medications
Participants with Concomitant Medications used from 28 days prior to screening until the final visit or end of study (EOS) were reported. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Overall Study Period
Maximum Serum Concentration Observed (Cmax) of Idasanutlin
Cmax is the maximum observed concentration of drug in blood. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Trough Concentration (Ctrough) of Idasanutlin
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Time of Maximum Concentration Observed (Tmax) of Idasanutlin
Tmax is the time elapsed from the time of drug administration to maximum plasma concentration. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Clearance (CL) of Idasanutlin
CL is a measure of the body's elimination of a drug from plasma over time. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Apparent Clearance (CL/F) of Idasanutlin
CL/F is a measure of the body's elimination of a drug from plasma over time, after oral administration. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Volume or Apparent Volume of Distribution (Vdss/F) of Idasanutlin
Vdss/F is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the plasma. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Area Under the Concentration-Time Curve (AUC) of Idasanutlin
AUC (from zero to infinity) represents the total drug exposure over time. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Half-life (t1/2) of Idasanutlin
t1/2 is defined as the time required for the drug plasma concentration to be reduced to half. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time frame: Days 1, 2, and 5 of Cycles 1 and 4
Baseline and Mean Change From Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Over Time
MPN-SAF Total Symptom Score is the sum of the following 10 items: early satiety, abdominal discomfort, inactivity, concentration issues, night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months and fatigue. The participant provides a severity score for each symptom on a scale of 0 as a minimum score (none/absent) to 10 (worst imaginable) as a maximum score. Baseline (Cycle 1, Day 1) MPN-SAF total symptom score and the mean change from baseline score at each timepoint are reported. The change from baseline score was calculated by subtracting the post-baseline score from the baseline score. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
Time frame: Baseline (Cycle 1 Day 1), Cycle 2 Day 1, Days 28 of Cycles 3, 5, 8 (Week 32), 11, 14, 17 ) Day 28, Cycle 5 Day 28, End of Cycle 8 (Week 32), and Final Visit
Baseline and Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores Over Time
Reported EORTC QLQ-C30 Scores include: Cognitive function, Diarrhea Emotional functioning, Nausea and vomiting, Social functioning, Physical functioning, Global health status/QoL and Role functioning. The questions use a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores are averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
Time frame: Baseline (Cycle 1 Day 1), Cycle 2 Day 1, Cycles 3, 5, 8, 11, 14, 17, 20 Day 28 and Final Visit
Frequency Count of Participant Responses to the Patient Global Impression of Change (PGIC) Question Over Time
The PGIC is a one-item measure used to assess perceived treatment benefit. Participants were asked "Since the start of the treatment you've received in this study, your polycythemia vera (PV) symptoms are: 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse'. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
Time frame: Cycle 2 Day 1, Cycle 3 Day 28, Cycle 5 Day 28, End of Cycle 8 (Week 32), and every 3 cycles thereafter (1 cycle is 28 days) until end of study (up to 2 years)
A total of 48 participants were screened for enrollment; 21 were failed screening. 27 were enrolled and received study treatment. All 27 patients were discontinued from study before the planned date of follow-up.
| Milestone | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Started | 15 | 5 | 6 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 15 | 5 | 6 | 1 |
| Withdrew: Study terminated by sponsor | 3 | 0 | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 3 | 3 | 0 |
| Withdrew: Physician decision | 3 | 2 | 0 | 0 |
Composite response is defined as hematocrit (Hct) control without phlebotomy and ≥35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of ≥45% that was ≥3% higher than baseline level or a Hct of \>48%. One Cycle is 28 Days.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly |
|---|---|
| Percentage of Ruxolitinib-Naïve Participants With Splenomegaly at Baseline Who Achieved Composite Response at Week 32 | 44.4 |
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
| Percentage of Participants | Ruxolitinib-Naïve Participants Without Splenomegaly |
|---|---|
| Percentage of Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline Who Achieved Hematocrit (Hct) Control Without Phlebotomy at Week 32 | 100 |
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Naïve Participants Without Splenomegaly | Total Ruxolitinib-Naïve Participants |
|---|---|---|---|
| Percentage of All Ruxolitinib-Naïve Participants (Irrespective of Spleen Size) Who Achieved Hct Control Without Phlebotomy at Week 32 | 44.4 | 100 | 54.5 |
Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
| Percentage of Participants | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | Total Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|---|
| Percentage of All Ruxolitinib-Resistant or Intolerant Participants Who Achieved Hct Control Without Phlebotomy at Week 32 | 75.0 | 0 | 60 |
Complete hematologic response requires all of the following: Hct control without phlebotomy; White blood cell (WBC) count ≤10 × 10\^9/Liter (L) at Week 32; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
| Percentage of Participants | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Response at Week 32 | 33.3 | 100 | 75.0 | 0 |
Complete hematologic remission requires all of the following: Hct control without phlebotomy between Weeks 32 and Cycle 11 Day 28; WBC count ≤10 × 10\^9/L at Cycle 11 Day 28; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Remission at Cycle 11 Day 28 | 40 | 100 | 0 | 0 |
Complete hematologic remission requires all of the following: Hct control without phlebotomy between Week 32 (Cycle 8 Day 28) and Cycle 11 Day 28; WBC count ≤10 × 10\^9/L at Cycle 11 Day 28; and Platelet count ≤400 × 10\^9/L at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy. Eligibility for phlebotomy is defined as a Hct level ≥45% that was ≥3% higher than baseline level or a Hct level of \>48%
| Participants | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Cycle 11, Day 28 | 2 | 1 | 0 | 0 |
| Week 32 | 3 | 2 | 3 | 0 |
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly |
|---|---|---|
| Baseline Complete Response | 0 | 0 |
| Baseline Partial Response | 0 | 0 |
| Baseline Progressive Disease | 0 | 0 |
| Baseline No Response | 0 | 0 |
| Cycle 3, Day 28 Complete Response | 0 | 33.3 |
| Cycle 3, Day 28 Partial Response | 73.3 | 50.0 |
| Cycle 3, Day 28 Progressive Disease | 0 | 0 |
| Cycle 3, Day 28 No Response | 26.7 | 16.7 |
| Cycle 5, Day 28 Complete Response | 0 | 0 |
| Cycle 5, Day 28 Partial Response | 76.9 | 80.0 |
| Cycle 5, Day 28 Progressive Disease | 0 | 0 |
| Cycle 5, Day 28 No Response | 23.1 | 20.0 |
| Cycle 8, Day 28 (Week 32) Complete Response | 0 | 25.0 |
| Cycle 8, Day 28 (Week 32) Partial Response | 66.7 | 50.0 |
| Cycle 8, Day 28 (Week 32) Progressive Disease | 0 | 0 |
| Cycle 8, Day 28 (Week 32) No Response | 33.3 | 25.0 |
| Cycle 11, Day 28 Complete Response | 0 | 0 |
| Cycle 11, Day 28 Partial Response | 80.0 | 100.0 |
| Cycle 11, Day 28 Progressive Disease | 0 | 0 |
| Cycle 11, Day 28 No Response | 20.0 | 0 |
| Cycle 12, Day 28 Complete Response | — | 0 |
| Cycle 12, Day 28 Partial Response | — | 0 |
| Cycle 12, Day 28 Progressive Disease | — | 0 |
| Cycle 12, Day 28 No Response | — | 0 |
| Cycle 14, Day 28 Complete Response | 0 | 0 |
| Cycle 14, Day 28 Partial Response | 80 | 100 |
| Cycle 14, Day 28 Progressive Disease | 0 | 0 |
| Cycle 14, Day 28 No Response | 20 | 0 |
| Cycle 17, Day 28 Complete Response | 0 | 0 |
| Cycle 17, Day 28 Partial Response | 33.3 | 0 |
| Cycle 17, Day 28 Progressive Disease | 0 | 0 |
| Cycle 17, Day 28 No Response | 66.7 | 100 |
| Cycle 20, Day 28 Complete Response | 0 | — |
| Cycle 20, Day 28 Partial Response | 100 | — |
| Cycle 20, Day 28 Progressive Disease | 0 | — |
| Cycle 20, Day 28 No Response | 0 | — |
| Final Visit (28 Days post-last dose) Complete Response | 0 | 0 |
| Final Visit (28 Days post-last dose) Partial Response | 20.0 | 33.3 |
| Final Visit (28 Days post-last dose) Progressive Disease | 0 | 0 |
| Final Visit (28 Days post-last dose) No Response | 80 | 66.7 |
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|
| Baseline Complete Response | 0 | 0 |
| Baseline Partial Response | 0 | 0 |
| Baseline Progressive Disease | 0 | 0 |
| Baseline No Response | 0 | 0 |
| Cycle 3, Day 28 Complete Response | 50 | 0 |
| Cycle 3, Day 28 Partial Response | 50 | 0 |
| Cycle 3, Day 28 Progressive Disease | 0 | 0 |
| Cycle 3, Day 28 No Response | 0 | 100 |
| Cycle 5 Day 28 Complete Response | 66.7 | 0 |
| Cycle 5 Day 28 Partial Response | 33.3 | 0 |
| Cycle 5 Day 28 Progressive Disease | 0 | 0 |
| Cycle 5 Day 28 No Response | 0 | 100 |
| Cycle 8, Day 28 (Week 32) Complete Response | 100 | 0 |
| Cycle 8, Day 28 (Week 32) Partial Response | 0 | 0 |
| Cycle 8, Day 28 (Week 32) Progressive Disease | 0 | 0 |
| Cycle 8, Day 28 (Week 32) No Response | 0 | 100 |
| Cycle 11, day 28 Complete Response | 100 | 0 |
| Cycle 11, day 28 Partial Response | 0 | 0 |
| Cycle 11, day 28 Progressive Disease | 0 | 0 |
| Cycle 11, day 28 No Response | 0 | 100 |
| Cycle 14, Day 28 Complete Response | 100 | 0 |
| Cycle 14, Day 28 Partial Response | 0 | 0 |
| Cycle 14, Day 28 Progressive Disease | 0 | 0 |
| Cycle 14, Day 28 No Response | 0 | 100 |
| Cycle 17, Day 28 Complete Response | 100 | 0 |
| Cycle 17, Day 28 Partial Response | 0 | 0 |
| Cycle 17, Day 28 Progressive Disease | 0 | 0 |
| Cycle 17, Day 28 No Response | 0 | 100 |
| Cycle 20, Day 28 Complete Response | — | 0 |
| Cycle 20, Day 28 Partial Response | — | 0 |
| Cycle 20, Day 28 Progressive Disease | — | 0 |
| Cycle 20, Day 28 No Response | — | 100 |
| Final (28 Days post-last dose) Complete Response | 50.0 | 0 |
| Final (28 Days post-last dose) Partial Response | 25.0 | 0 |
| Final (28 Days post-last dose) Progressive Disease | 0.0 | 0 |
| Final (28 Days post-last dose) No Response | 25.0 | 100 |
Complete response (CR) includes all of the following: Hct \<45% without phlebotomy; Platelet count ≤400 × 10\^9/L; WBC count ≤10 × 10\^9/L; Normal spleen size on imaging; and No disease-related symptoms. Partial response (PR): in participants who do not fulfill the criteria for CR: Hct \<45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia. All responders of each category grouped per timepoint include all categories mentioned above. There were no PD responses at any timepoint. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
| Percentage of Participants | All Ruxolitinib-Naïve Participants | All Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| Baseline Complete Response | 0 | 0 |
| Baseline Partial Response | 0 | 0 |
| Baseline Progressive Disease | 0 | 0 |
| Baseline No Response | 0 | 0 |
| Cycle 3, Day 28 Complete Response | 10.5 | 28.6 |
| Cycle 3, Day 28 Partial Response | 68.4 | 42.9 |
| Cycle 3, Day 28 Progressive Disease | 0 | 0 |
| Cycle 3, Day 28 No Response | 21.1 | 28.6 |
| Cycle 5, Day 28 Complete Response | 12.5 | 0 |
| Cycle 5, Day 28 Partial Response | 68.8 | 66.7 |
| Cycle 5, Day 28 Progressive Disease | 0 | 0 |
| Cycle 5, Day 28 No Response | 18.8 | 33.3 |
| Cycle 8, Day 28 (Week 32) Complete Response | 18.2 | 20.0 |
| Cycle 8, Day 28 (Week 32) Partial Response | 54.5 | 40.0 |
| Cycle 8, Day 28 (Week 32) Progressive Disease | 0 | 0 |
| Cycle 8, Day 28 (Week 32) No Response | 27.3 | 40.0 |
| Cycle 11 Day 28 Complete Response | 16.7 | 0 |
| Cycle 11 Day 28 Partial Response | 66.7 | 50.0 |
| Cycle 11 Day 28 Progressive Disease | 0 | 0 |
| Cycle 11 Day 28 No Response | 16.7 | 50.0 |
| Cycle 12 Day 28 Complete Response | — | 0 |
| Cycle 12 Day 28 Partial Response | — | 100 |
| Cycle 12 Day 28 Progressive Disease | — | 0 |
| Cycle 12 Day 28 No Response | — | 0 |
| Cycle 14, Day 28 Complete Response | 16.7 | 0 |
| Cycle 14, Day 28 Partial Response | 66.7 | 50 |
| Cycle 14, Day 28 Progressive Disease | 0 | 0 |
| Cycle 14, Day 28 No Response | 16.7 | 50.0 |
| Cycle 17, Day 28 Complete Response | 25.0 | 0 |
| Cycle 17, Day 28 Partial Response | 25.0 | 0 |
| Cycle 17, Day 28 Progressive Disease | 0 | 0 |
| Cycle 17, Day 28 No Response | 50.0 | 100 |
| Cycle 20, Day 28 Complete Response | 0 | 0 |
| Cycle 20, Day 28 Partial Response | 100 | 0 |
| Cycle 20, Day 28 Progressive Disease | 0 | 0 |
| Cycle 20, Day 28 No Response | 0 | 100 |
| Final Visit Complete Response | 14.3 | 0 |
| Final Visit Partial Response | 21.4 | 25.0 |
| Final Visit Progressive Disease | 0 | 0 |
| Final Visit No Response | 64.3 | 75.0 |
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 are analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly |
|---|---|---|
| HCT Control | 42.9 | 100 |
| Composite Response | 0 | 0 |
| ELN Response | 50 | 75 |
| Complete Hematologic Response | 28.6 | 66.7 |
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly |
|---|---|---|
| HCT Control | 3 | 3 |
| Composite Response | 0 | 0 |
| ELN Response | 4 | 3 |
| Complete Hematologic Response | 2 | 2 |
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|
| HCT Control | 100 | 0 |
| Composite Response | 0 | 0 |
| ELN Response | 100 | 0 |
| Complete Hematologic Response | 100 | 0 |
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Participants | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|
| HCT Control | 2 | 0 |
| Composite Response | 0 | 0 |
| ELN Response | 2 | 0 |
| Complete Hematologic Response | 2 | 0 |
The percentage of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor decision, therefore did not reach the end of study.
| Percentage of Participants | All Ruxolitinib-Naïve Participants | All Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| After 12 Weeks from Week 32 HCT Control | 55.6 | 75 |
| After 12 Weeks from Week 32 Composite Response | 0 | 0 |
| After 12 Weeks from Week 32 ELN Response | 60 | 60 |
| After 12 Weeks from Week 32 Complete Hematologic Response | 44.4 | 50 |
The number of participants with a durable response lasting at least 12 weeks from Week 32 is analyzed by the type of response achieved: Hct control, complete hematologic response, ELN 2009 response criteria, and composite response, if applicable. Reported result data start from Cycle 11 Day 28 which is 12 weeks after Week 32 (Cycle 8 Day 28). There was one timepoint for which the participants qualify. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Participants | All Ruxolitinib-Naïve Participants | All Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| HCT Control | 5 | 3 |
| Composite Response | 0 | 0 |
| ELN Response | 6 | 3 |
| Complete Hematologic Response | 4 | 2 |
An adverse event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. The adverse event severity grading scale for the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0) will be used for assessing adverse event severity. During the final analyses, the focus was on the Adverse Events of severity grades \>/=3 as shown below. The extensive listings of all grade AEs are available at request. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 0 | 0 | 0 | 0 |
| Grade 3-5 AE | 5 | 2 | 3 | 0 |
Hematology parameter laboratory values falling outside the standard reference range were planned to be recorded as either high or low. There was no clinical laboratory abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of Participants With Clinical Laboratory Abnormalities: Hematology Parameters. | 0 | 0 | 0 | 0 |
Clinical chemistry parameter laboratory values falling outside the standard reference range were to be recorded as either high or low. There was no clinical chemistry abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-Naïve Participants With Splenomegaly | Ruxolitinib-Naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of Participants With Clinical Laboratory Abnormalities: Clinical Chemistry Parameters | 0 | 0 | 0 | 0 |
Urinalysis parameter laboratory values falling outside the standard reference range were planned to be recorded as either high or low. There was no clinical laboratory (urinalysis) abnormalities identified. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
| Percentage of Participants | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of Participants With Clinical Laboratory Abnormalities: Urinalysis Parameters | 0 | 0 | 0 | 0 |
Single 12-lead ECGs was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Millisecond (msec) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| PR Duration Baseline | 158.93 ± 24.86 | 153.60 ± 22.55 | 152.00 ± 17.39 | 196.00 ± 0 |
| PQ(PR) Durations Cycle 1, Day 1, 4 hour | 0.60 ± 10.89 | -2.60 ± 5.37 | -2.00 ± 9.72 | 4.00 ± 0 |
| PQ(PR) Durations Cycle 1, Day 1, 6 hour | -2.80 ± 8.10 | -4.40 ± 15.52 | 6.00 ± 25.49 | 0.00 ± 0 |
| PQ(PR) Durations Cycle 1, Day 2, pre-dose | -14.00 ± 0 | -6.00 ± 0 | — | — |
| PQ(PR) Durations Cycle 1, Day 2, 24 hour | 1.93 ± 10.32 | 1.00 ± 16.45 | 0.67 ± 22.01 | -12.00 ± 0 |
| PQ(PR) Durations Cycle ,1 Day 5, pre-dose | -1.00 ± 11.70 | -12.00 ± 9.38 | 0.40 ± 26.59 | -4.00 ± 0 |
| PQ(PR) Durations Cycle 1, Day 5, 4 hour | -8.00 ± 12.68 | -6.25 ± 15.59 | -1.20 ± 29.52 | 0 ± 0 |
| PQ(PR) Durations Cycle 1, Day 5, 6 hour | -4.77 ± 14.08 | -2.75 ± 10.81 | 7.60 ± 27.29 | 0 ± 0 |
| PQ(PR) Durations Cycle 2, Day1, pre-dose | 1.43 ± 14.26 | -5.75 ± 11.79 | -2.33 ± 11.89 | -8.00 ± 0 |
| PQ(PR) Durations Cycle 3, Day 1, pre-dose | -6.00 ± 0 | — | — | — |
| PQ(PR) Durations Cycle 3, Day 1, 4 hour | -8.00 ± 0 | — | — | — |
| PQ(PR) Durations Cycle 3, Day 1, 6 hour | -6.00 ± 0 | — | — | — |
| PQ(PR) Durations Cycle 4, Day 1, pre-dose | -20.00 ± 0 | — | — | — |
| PQ(PR) Durations Cycle 4, Day 1, 4 hour | -20.00 ± 0 | — | — | — |
| QRS Duration Baseline | 90.87 ± 8.25 | 83.80 ± 6.42 | 83.33 ± 9.77 | 94.00 ± 0 |
| QRS Cycle 1 Day 1 (4 H) | -1.47 ± 5.83 | 4.60 ± 6.69 | 1.33 ± 1.03 | 0 ± 0 |
| QRS Cycle 1 Day 1 (6 H) | -1.27 ± 5.27 | 4.00 ± 3.08 | 0.33 ± 5.28 | -2.00 ± 0 |
| QRS Cycle 1 Day 2 (PREDOSE) | -4.00 ± 0 | 2.00 ± 0 | — | — |
| QRS Cycle 1 Day 2 (24 H) | 1.07 ± 3.77 | 1.75 ± 6.55 | 3.00 ± 11.64 | -2.00 ± 0 |
| QRS Cycle 1 Day 5 (PREDOSE) | 0.13 ± 4.63 | 4.00 ± 9.09 | 0.00 ± 2.00 | 2.00 ± 0 |
| QRS Cycle 1 Day 5 (4 H) | -1.08 ± 3.12 | 3.75 ± 9.46 | -0.40 ± 2.61 | 0 ± 0 |
| QRS Cycle 1 Day 5 (6 H) | -0.92 ± 4.73 | -0.25 ± 5.19 | 2.00 ± 5.83 | 0 ± 0 |
| QRS Cycle 2 Day 1 (PREDOSE) | 0.64 ± 6.25 | 7.75 ± 9.46 | 1.00 ± 2.76 | -4.00 ± 0 |
| QRS Cycle 3 Day 1 (PREDOSE) | -4.00 ± 0 | — | — | — |
| QRS Cycle 3 Day 1 (4 H) | -4.00 ± 0 | — | — | — |
| QRS Cycle 3 Day 1 (6 H) | -4.00 ± 0 | — | — | — |
| QRS Cycle 4 Day 1 (PREDOSE) | -2.00 ± 0 | — | — | — |
| QRS Cycle 4 Day 1 (4 H) | -2.00 ± 0 | — | — | — |
| QT Duration Baseline | 396.67 ± 31.96 | 392.60 ± 38.74 | 386.00 ± 16.78 | 392.00 ± 0 |
| QT Duration Cycle 1 Day 1 (4 H) | -7.33 ± 26.43 | 16.80 ± 13.44 | 5.67 ± 10.07 | 36.00 ± 0 |
| QT Duration Cycle 1 Day 1 (6 H) | -9.40 ± 23.70 | 11.00 ± 29.14 | -1.33 ± 13.49 | 36.00 ± 0 |
| QT Duration Cycle 1 Day 2 (PREDOSE) | -6.00 ± 0 | -18.00 ± 0 | — | — |
| QT Duration Cycle 1 Day 2 (24 H) | -10.21 ± 25.57 | 2.75 ± 29.00 | 7.00 ± 16.58 | 0 ± 0 |
| QT Duration Cycle 1 Day 5 (PREDOSE) | -6.20 ± 19.79 | -8.75 ± 21.00 | 8.00 ± 19.54 | 4.00 ± 0 |
| QT Duration Cycle 1 Day 5 (4 H) | -4.31 ± 33.31 | 15.25 ± 15.65 | 3.20 ± 24.23 | -12.00 ± 0 |
| QT Duration Cycle 1 Day 5 (6 H) | -10.31 ± 24.83 | 4.75 ± 20.93 | 7.60 ± 16.40 | -4.00 ± 0 |
| QT Duration Cycle 2 Day 1 (PREDOSE) | 5.00 ± 22.68 | 10.50 ± 25.96 | 19.00 ± 13.67 | 12.00 ± 0 |
| QT Durations Cycle 3 Day 1 (PREDOSE) | -2.00 ± 0 | — | — | — |
| QT Durations Cycle 3 Day 1 (4 H) | -10.00 ± 0 | — | — | — |
| QT Durations Cycle 3 Day 1 (6 H) | -4.00 ± 0 | — | — | — |
| QT Durations Cycle 4 Day 1 (PREDOSE) | -16.00 ± 0 | — | — | — |
| QT Durations Cycle 4 Day 1 (4 H) | -16.00 ± 0 | — | — | — |
| QTcB baseline | 427.67 ± 24.23 | 419.60 ± 7.70 | 424.50 ± 25.74 | 444.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 1 Day 1 (4 H) | 3.80 ± 12.82 | 21.00 ± 11.14 | 13.83 ± 14.05 | -30.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 1 Day 1 (6 H) | 8.00 ± 10.54 | 8.40 ± 22.40 | 6.33 ± 5.50 | 5.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 1 Day 2 (PREDOSE) | -15.00 ± 0 | -410.00 ± 0 | — | — |
| QTcB - Bazett's Correction Formula Cycle 1 Day 2 (24 H) | 3.71 ± 15.59 | -0.75 ± 16.40 | 4.50 ± 14.47 | -14.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 1 Day 5 (PREDOSE) | -11.07 ± 15.21 | -10.00 ± 8.76 | -9.20 ± 15.25 | -7.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 4 Day 1 (4 H) | -62.00 ± 0 | — | — | — |
| QTcB - Bazett's Correction FormulaCycle 1 Day 5 (4 H) | -2.92 ± 14.20 | 1.50 ± 8.81 | -4.60 ± 18.70 | 0.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 1 Day 5 (6 H) | -4.54 ± 16.10 | -4.75 ± 6.18 | -1.60 ± 15.44 | -12.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 2 Day 1 (PREDOSE) | 3.93 ± 14.42 | 7.75 ± 20.61 | 0.17 ± 14.54 | -23.00 ± 0 |
| QTcB - Bazett's Correction Formula Cycle 3 Day 1 (PREDOSE) | -16.00 ± 0 | — | — | — |
| QTcB - Bazett's Correction Formula Cycle 3 Day 1 (4 H) | 6.00 ± 0 | — | — | — |
| QTcB - Bazett's Correction Formula Cycle 3 Day 1 (6 H) | 8.00 ± 0 | — | — | — |
| QTcB - Bazett's Correction Formula Cycle 4 Day 1 (PREDOSE) | -62.00 ± 0 | — | — | — |
| QTcB - Bazett's Correction Formula Cycle 4 Day 1, 4 H | -62.00 ± 0 | — | — | — |
| QTcF Durations Fridericia's Correction Formula Baseline | 417.93 ± 22.41 | 410.00 ± 17.62 | 411.17 ± 17.90 | 426.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 1 (4 H) | -1.27 ± 11.86 | 18.80 ± 10.08 | 11.67 ± 11.09 | -8.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 1 (6 H) | 1.00 ± 8.78 | 10.00 ± 21.64 | 3.50 ± 7.37 | 16.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 2 (PREDOSE) | -12.00 ± 0 | -20.00 ± 0 | — | — |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 2 (24 H) | -2.36 ± 13.32 | 0.00 ± 20.46 | 5.33 ± 14.81 | -9.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 5 (PREDOSE) | -10.47 ± 14.17 | -9.25 ± 8.96 | -3.20 ± 14.60 | -3.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 5 (4 H) | -0.08 ± 26.39 | 4.00 ± 8.98 | -2.00 ± 17.36 | -4.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 1 Day 5 (6 H) | -7.85 ± 13.44 | -2.25 ± 8.46 | 1.60 ± 14.10 | 6.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 2 Day 1 (PREDOSE) | 3.36 ± 10.49 | 8 ± 20.51 | 6.83 ± 12.45 | -11.00 ± 0 |
| QTcF Durations Fridericia's Correction Formula Cycle 3 Day 1 (PREDOSE) | -11.00 ± 0 | — | — | — |
| QTcF Durations Fridericia's Correction Formula Cycle 3 Day 1 (4 H) | 0.00 ± 0 | — | — | — |
| QTcF Durations Fridericia's Correction Formula Cycle 3 Day 1 (6 H) | 4.00 ± 0 | — | — | — |
| QTcF Durations Fridericia's Correction Formula Cycle 4 Day 1 (PREDOSE) | -45.00 ± 0 | — | — | — |
| QTcF Durations Fridericia's Correction Formula Cycle 4 Day 1 (4 H) | -45.00 ± 0 | — | — | — |
| RR Duration Baseline | 861.47 ± 133.95 | 881.00 ± 151.46 | 835.83 ± 139.93 | 779.00 ± 0 |
| RR Duration Cycle 1 Day 1 4 H | -38.87 ± 130.21 | -5.60 ± 58.23 | -36.50 ± 66.76 | 292.00 ± 0 |
| RR Duration Cycle 1 Day 1 6 H | -65.67 ± 117.44 | 14.00 ± 100.82 | -31.17 ± 49.04 | 130.00 ± 0 |
| RR Duration Cycle 1 Day 2 (PREDOSE) | 28.00 ± 0 | 18.00 ± 0 | — | — |
| RR Duration Cycle 1 Day 2 (24 H) | -51.50 ± 121.75 | 17.25 ± 65.17 | 8.83 ± 29.78 | 54.00 ± 0 |
| RR Duration Cycle 1 Day 5 (PREDOSE) | 25.87 ± 97.32 | -0.75 ± 104.53 | 67.80 ± 78.89 | 43.00 ± 0 |
| RR Duration Cycle 1 Day 5 (4 H) | -26.23 ± 114.00 | 79.75 ± 62.99 | 24.20 ± 114.05 | -47.00 ± 0 |
| RR Duration Cycle 1 Day 5 (6 H) | -21.46 ± 121.82 | 49.50 ± 99.21 | 33.00 ± 59.05 | -56.00 ± 0 |
| RR Duration Cycle 2 Day 1 (PREDOSE) | 7.14 ± 118.26 | 23.75 ± 86.53 | 78.17 ± 59.85 | 144.00 ± 0 |
| RR Duration Cycle 3 Day 1 (PREDOSE) | 48.00 ± 0 | — | — | — |
| RR Duration Cycle 3 Day 1 (4 H) | -59.00 ± 0 | — | — | — |
| RR Duration Cycle 3 Day 1 (6 H) | -43.00 ± 0 | — | — | — |
| RR Duration Cycle 4 Day 1 (PREDOSE) | 182.00 ± 0 | — | — | — |
| RR Duration Cycle 4 Day 1 (4 H) | 182.00 ± 0 | — | — | — |
Single 12-lead ECGs was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Beats per Minute | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 71.47 ± 12.74 | 69.80 ± 12.28 | 73.17 ± 10.07 | 77.00 ± 0 |
| Cycle 1, Day 1, 4 Hour | 4.40 ± 10.58 | 0.60 ± 5.32 | 2.50 ± 4.23 | -21.00 ± 0 |
| Cycle 1, Day 1, 6 Hour | 6.20 ± 10.35 | -0.60 ± 8.65 | 3.00 ± 5.44 | -11.00 ± 0 |
| Cycle 1 Day 2, pre-dose | -3.00 ± 0 | -1.00 ± 0 | — | — |
| Cycle 1 Day 2, 24 Hour | 4.71 ± 10.31 | -1.75 ± 5.32 | -0.67 ± 2.50 | -5.00 ± 0 |
| Cycle 1 Day 5, pre-dose | -1.47 ± 6.56 | -0.75 ± 8.14 | -5.60 ± 5.27 | -4.00 ± 0 |
| Cycle 1 Day 5, 4 hour | 2.69 ± 8.61 | -5.00 ± 2.94 | -2.20 ± 7.92 | 5.00 ± 0 |
| Cycle 1 Day 5, 6 hour | 2.23 ± 9.39 | -3.75 ± 7.76 | -2.80 ± 4.92 | 6.00 ± 0 |
| Cycle 2, Day 1, pre-dose | -1.43 ± 9.83 | -1.50 ± 8.39 | -6.17 ± 5.19 | -12.00 ± 0 |
| Cycle 3 Day 1, pre-dose | -5.00 ± 0 | — | — | — |
| Cycle 3 Day 1, 4 hour | 7.00 ± 0 | — | — | — |
| Cycle 3 Day 1, 6 hour | 5.00 ± 0 | — | — | — |
| Cycle 4 Day 1, pre-dose | -16.00 ± 0 | — | — | — |
| Cycle 4 Day 1, 4 hour | -16.00 ± 0 | — | — | — |
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
| Degrees Celsius (C) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 36.50 ± 0.37 | 36.40 ± 0.25 | 36.47 ± 0.28 | 37.10 ± 0 |
| Cycle 1 Day 15 | 0.13 ± 0.33 | 0.42 ± 0.50 | 0.18 ± 0.32 | -0.30 ± 0 |
| Cycle 1 Day 22 | 0.03 ± 0.18 | 0.04 ± 0.29 | 0.15 ± 0.21 | -0.50 ± 0 |
| Cycle 2 Day 1 | -0.05 ± 0.28 | 0.05 ± 0.30 | 0.17 ± 0.34 | -0.60 ± 0 |
| Cycle 2 Day 15 | 0.04 ± 0.27 | 0.18 ± 0.24 | 0.23 ± 0.38 | -0.30 ± 0 |
| Cycle 3 Day 1 | -0.09 ± 0.36 | 0.13 ± 0.45 | 0.17 ± 0.43 | 0.10 ± 0 |
| Cycle 3 Day 15 | -0.04 ± 0.31 | -0.03 ± 0.06 | 0.10 ± 0.26 | -0.20 ± 0 |
| Cycle 4 Day 1 | -0.05 ± 0.26 | -0.17 ± 0.15 | 0.06 ± 0.37 | -0.50 ± 0 |
| Cycle 5 Day 1 | 0.05 ± 0.16 | -0.10 ± 0.36 | 0.10 ± 0.32 | -0.80 ± 0 |
| Cycle 6 Day 1 | -0.03 ± 0.16 | -0.10 ± 0.45 | 0.12 ± 0.16 | -0.40 ± 0 |
| Cycle 7 Day 1 | 0.01 ± 0.30 | -0.20 ± 0.28 | 0.20 ± 0.26 | -0.60 ± 0 |
| Cycle 8 Day 1 | -0.01 ± 0.20 | -0.05 ± 0.64 | 0.20 ± 0.36 | -0.30 ± 0 |
| Cycle 9 Day 1 | 0.03 ± 0.13 | 0.05 ± 0.35 | -0.07 ± 0.42 | -0.40 ± 0 |
| Cycle 10 Day 1 | -0.08 ± 0.10 | 0.30 ± 0.42 | 0.10 ± 0.35 | -0.60 ± 0 |
| Cycle 11 Day 1 | -0.07 ± 0.19 | -0.20 ± 0 | -0.10 ± 0.14 | -0.40 ± 0 |
| Cycle 12 Day 1 | -0.10 ± 0.16 | 0.30 ± 0 | -0.20 ± 0.14 | -0.70 ± 0 |
| Cycle 13 Day 1 | 0.00 ± 0.19 | -0.70 ± 0 | 0 | -0.70 ± 0 |
| Cycle 14 Day 1 | 0.00 ± 0.41 | -0.10 ± 0 | -0.30 ± 0 | -0.70 ± 0 |
| Cycle 15 Day 1 | -0.10 ± 0.14 | -0.30 ± 0 | -0.40 ± 0 | -0.50 ± 0 |
| Cycle 16 Day 1 | 0.03 ± 0.30 | -0.80 ± 0 | -0.10 ± 0 | -0.50 ± 0 |
| Cycle 17 Day 1 | 0.03 ± 0.12 | 0.60 ± 0 | 0.00 ± 60 | -0.80 ± 0 |
| Cycle 18 Day 1 | 0.07 ± 0.15 | — | -0.20 ± 0 | -0.80 ± 0 |
| Cycle 19 Day 1 | -0.15 ± 0.21 | — | 0 | -0.50 ± 0 |
| Cycle 20 Day 1 | 0.00 ± 0.14 | — | 0 | -0.50 ± 0 |
| Cycle 21 Day 1 | 0 ± 0 | — | — | -0.40 ± 0 |
| Cycle 22 Day 1 | -0.50 ± 0 | — | — | -0.70 ± 0 |
| Cycle 23 Day 1 | — | — | — | -0.80 ± 0 |
| Final Visit | -0.08 ± 0.15 | 0.26 ± 0.26 | 0.08 ± 0.37 | -0.50 ± 0 |
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Beats per Minute | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 74.7 ± 12.3 | 71.6 ± 9.2 | 76.7 ± 14.1 | 68.0 ± 0 |
| Cycle 1 Day 15 | 4.5 ± 13.2 | 5.4 ± 5.5 | -0.7 ± 4.8 | 7.0 ± 0 |
| Cycle 1 Day 22 | 3.9 ± 11.3 | 8.2 ± 4.9 | -5.8 ± 3.9 | 8.0 ± 0 |
| Cycle 2 Day 1 | -1.1 ± 8.6 | 1.8 ± 8.7 | -9.3 ± 6.1 | 12.0 ± 0 |
| Cycle 2 Day 15 | 0.1 ± 11.0 | 1.8 ± 8.5 | -5.8 ± 5.5 | 9.0 ± 0 |
| Cycle 3 Day 1 | -2.8 ± 9.4 | -2.0 ± 8.6 | -4.2 ± 9.9 | 9.0 ± 0 |
| Cycle 3 Day 15 | -1.2 ± 9.7 | 10.8 ± 13.6 | -2.2 ± 11.0 | 21.0 ± 0 |
| Cycle 4 Day 1 | 1.0 ± 11.2 | 1.7 ± 9.9 | -6.6 ± 9.8 | 24.0 ± 0 |
| Cycle 5 Day 1 | 0.6 ± 8.4 | -4.0 ± 9.3 | -3.6 ± 4.2 | 28.0 ± 0 |
| Cycle 6 Day 1 | 0.4 ± 9.1 | -4.3 ± 6.8 | -1.6 ± 6.8 | 14.0 ± 0 |
| Cycle 7 Day 1 | 1.4 ± 14.6 | 1.5 ± 16.3 | -1.0 ± 9.8 | 21.0 ± 0 |
| Cycle 8 Day 1 | -3.9 ± 13.3 | -1.0 ± 12.7 | 0.5 ± 3.1 | 11.0 ± 0 |
| Cycle 9 Day 1 | -5.4 ± 6.4 | 0.0 ± 5.7 | 0.3 ± 2.5 | 0 ± 0 |
| Cycle 10 Day 1 | -0.3 ± 9.9 | 8.5 ± 19.1 | 2.3 ± 8.5 | 20.0 ± 0 |
| Cycle 11 Day 1 | -2.5 ± 11.5 | -2.0 ± 0 | 2.5 ± 0.7 | 37.0 ± 0 |
| Cycle 12, Day 1 | -0.2 ± 11.6 | -6.0 ± 0 | -1.0 ± 4.2 | 21.0 ± 0 |
| Cycle 13, Day 1 | -2.8 ± 7.8 | -5.0 ± 0 | -1.0 ± 0 | 16.0 ± 0 |
| Cycle 14, Day 1 | -3.8 ± 11.1 | -2.0 ± 0 | -4.0 ± 0 | 12.0 ± 0 |
| Cycle 15 Day 1 | -0.8 ± 10.4 | 10.0 ± 0 | -2.0 ± 0 | 14.0 ± 0 |
| Cycle 16 Day 1 | -1.3 ± 15.6 | -2.0 ± 0 | -2.0 ± 0 | 16.0 ± 0 |
| Cycle 17, Day 1 | -12.7 ± 9.5 | 9.0 ± 0 | 1.0 ± 0 | 22.0 ± 0 |
| Cycle 18, Day 1 | -4.3 ± 3.5 | — | -3.0 ± 0 | 16.0 ± 0 |
| Cycle 19, Day 1 | -9.0 ± 5.7 | — | 6.0 ± 0 | 15.0 ± 0 |
| Cycle 20, Day 1 | -5.0 ± 9.9 | — | 4.0 ± 0 | 5.0 ± 0 |
| Cycle 21, Day 1 | 2.0 ± 0 | — | — | 17.0 ± 0 |
| Cycle 22, Day 1 | -8.0 ± 0 | — | — | 14 ± 0 |
| Cycle 23, Day 1 | — | — | — | 19.0 ± 0 |
| Final Visit | -1.7 ± 12.2 | 0.2 ± 11.6 | 0.2 ± 10.1 | 16.0 ± 0 |
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Breaths per Minute | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 17.4 ± 2.0 | 17.4 ± 1.9 | 18.2 ± 2.6 | 16.0 ± 0 |
| Cycle 1 Day 15 | -0.3 ± 1.0 | -0.2 ± 1.8 | -0.2 ± 1.8 | 0 ± 0 |
| Cycle 1 Day 22 | -0.5 ± 0.8 | 0.2 ± 0.4 | -0.5 ± 2.2 | 0 ± 0 |
| Cycle 2 Day 1 | -0.3 ± 1.5 | -0.3 ± 1.7 | -0.4 ± 1.7 | 0 ± 0 |
| Cycle 2 Day 15 | -0.2 ± 1.0 | 0.0 ± 0.8 | -1.2 ± 1.8 | 2.0 ± 0 |
| Cycle 3 Day 1 | -0.7 ± 1.3 | -1.5 ± 3.1 | -1.8 ± 1.8 | 0 ± 0 |
| Cycle 3 Day 15 | -0.7 ± 1.3 | 0.0 ± 1.0 | -1.0 ± 1.0 | 0 ± 0 |
| Cycle 4 Day 1 | -0.3 ± 1.3 | -3.3 ± 4.2 | -1.0 ± 1.0 | 2.0 ± 0 |
| Cycle 5 Day 1 | -0.4 ± 1.9 | -0.3 ± 0.6 | 1.0 ± 2.2 | 0 ± 0 |
| Cycle 6 Day 1 | -0.5 ± 1.3 | -0.5 ± 1.9 | -0.6 ± 1.3 | 2.0 ± 0 |
| Cycle 7 Day 1 | -0.2 ± 1.7 | 0 ± 0 | -2.3 ± 1.5 | 2.0 ± 0 |
| Cycle 8 Day 1 | 0.1 ± 1.5 | -0.5 ± 2.1 | -0.8 ± 3.8 | 0 ± 0 |
| Cycle 9 Day 1 | 0.4 ± 1.8 | 0.5 ± 0.7 | -1.7 ± 6.0 | -2.0 ± 0 |
| Cycle 10 Day 1 | -0.2 ± 1.6 | -0.5 ± 2.1 | -0.3 ± 5.5 | 0 ± 0 |
| Cycle 11 Day 1 | -0.8 ± 1.0 | 1.0 ± 0 | -0.5 ± 0.7 | 2.0 ± 0 |
| Cycle 12 Day 1 | -0.4 ± 1.5 | 1.0 ± 0 | 1.5 ± 0.7 | 0 ± 0 |
| Cycle 13 Day 1 | -1.4 ± 2.8 | 1.0 ± 0 | -1.0 ± 0 | 2.0 ± 0 |
| Cycle 14 Day 1 | 0.8 ± 2.3 | 1.0 ± 0 | 1.0 ± 0 | 0 ± 0 |
| Cycle 15 Day 1 | 0.0 ± 1.4 | 1.0 ± 0 | -1.0 ± 0 | 0 ± 0 |
| Cycle 16 Day 1 | -0.3 ± 1.3 | 1.0 ± 0 | -2.0 ± 0 | 0 ± 0 |
| Cycle 17 Day 1 | 1.3 ± 2.3 | 1.0 ± 0 | -2.0 ± 0 | 0 ± 0 |
| Cycle 18 Day 1 | 1.3 ± 2.3 | — | -1.0 ± 0 | 2.0 ± 0 |
| Cycle 19 Day 1 | 1.5 ± 2.1 | — | -3.0 ± 0 | 2.0 ± 0 |
| Cycle 20 Day 1 | 2.0 ± 2.8 | — | -3.0 ± 0 | 2.0 ± 0 |
| Cycle 21 Day 1 | 2.0 ± 0 | — | — | 0 ± 0 |
| Cycle 22 Day 1 | 0.0 ± 0 | — | — | 0 ± 0 |
| Cycle 23 Day 1 | — | — | — | 0 ± 0 |
| Final visit | -0.3 ± 1.5 | -1.2 ± 1.5 | -1.8 ± 1.8 | 0 ± 0 |
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Millimeters of mercury (mmHg) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 129.3 ± 11.5 | 132.0 ± 17.2 | 122.3 ± 16.9 | 106.0 ± 0 |
| Cycle 1, Day 15 | 4.4 ± 9.9 | 3.6 ± 13.6 | 3.8 ± 15.1 | 5.0 ± 0 |
| Cycle 1, Days 22 | 3.3 ± 9.4 | -5.6 ± 11.8 | 4.8 ± 10.1 | -5.0 ± 0 |
| Cycle 2, Day 1 | 3.0 ± 10.3 | 2.8 ± 8.4 | -4.3 ± 7.9 | 10.0 ± 0 |
| Cycle 2 , Day 15 | 5.2 ± 9.8 | -2.0 ± 13.6 | -7.2 ± 9.6 | 30.0 ± 0 |
| Cycle 3, Day 1 | 5.5 ± 10.8 | -3.0 ± 9.8 | 7.3 ± 18.3 | 0 ± 0 |
| Cycle 3, Day 15 | 1.2 ± 11.2 | -3.5 ± 14.2 | -3.8 ± 16.7 | 6.0 ± 0 |
| Cycle 4, Day 1 | 2.2 ± 9.1 | -7.3 ± 9.3 | 9.8 ± 8.1 | 13.0 ± 0 |
| Cycle 5, Day 1 | 4.2 ± 10.5 | -2.5 ± 6.8 | 3.3 ± 6.9 | 16.0 ± 0 |
| Cycle 6 Day 1 | 11.2 ± 13.0 | 2.5 ± 9.7 | 8.6 ± 10.8 | 8.0 ± 0 |
| Cycle 7 Day 1 | 4.7 ± 4.2 | -4.0 ± 15.6 | 10.0 ± 5.0 | 29.0 ± 0 |
| Cycle 8 Day 1 | 8.8 ± 9.0 | 5.0 ± 7.1 | 14.0 ± 18.8 | 9.0 ± 0 |
| Cycle 9 Day 1 | 12.6 ± 8.3 | 3.0 ± 9.9 | -4.3 ± 4.9 | 26.0 ± 0 |
| Cycle 10 Day 1 | 11.8 ± 9.9 | -3.0 ± 2.8 | 11.0 ± 13.2 | 30.0 ± 0 |
| Cycle 11 Day 1 | 8.5 ± 12.3 | 14.0 ± 0 | 11.0 ± 12.7 | 34.0 ± 0 |
| Cycle 12 Day 1 | 10.8 ± 11.5 | -8.0 ± 0 | 6.5 ± 3.5 | 6.0 ± 0 |
| Cycle 13 Day 1 | 13.4 ± 5.1 | -8.0 ± 0 | 8.0 ± 0 | 14.0 ± 0 |
| Cycle 14 Day 1 | 4.4 ± 14.7 | 18.0 ± 0 | 3.0 ± 0 | 14.0 ± 0 |
| Cycle 15 Day 1 | 13.6 ± 7.5 | 14.0 ± 0 | 4.0 ± 0 | 5.0 ± 0 |
| Cycle 16 Day 1 | 7.5 ± 8.6 | 8.0 ± 0 | 9.0 ± 0 | 4.0 ± 0 |
| Cycle 17 Day 1 | 9.3 ± 5.8 | 24.0 ± 0 | 7.0 ± 0 | 6.0 ± 0 |
| Cycle 18 Day 1 | 5.7 ± 4.2 | — | 9.0 ± 0 | 13.0 ± 0 |
| Cycle 19 Day 1 | 2.5 ± 3.5 | — | 9.0 ± 0 | 13.0 ± 0 |
| Cycle 20 Day 1 | 11.5 ± 9.2 | — | 9.0 ± 0 | 13.0 ± 0 |
| Cycle 21 Day 1 | -18.0 ± 0 | — | — | 7.0 ± 0 |
| Cycle 22 Day 1 | 24.0 ± 0 | — | — | 6.0 ± 0 |
| Cycle 23 Day 1 | — | — | — | 11.0 ± 0 |
| Final Visit | 1.3 ± 9.7 | 7.6 ± 16.2 | 12.8 ± 23.9 | 19.0 ± 0 |
Vital signs were measured prior to the infusion while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the planned end of study.
| Millimeters of mercury (mmHg) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline | 76.3 ± 7.8 | 73.2 ± 5.2 | 72.3 ± 9.0 | 65.0 ± 0 |
| Cycle1, Day 15 | 5.1 ± 8.7 | 10.0 ± 8.7 | -1.8 ± 3.4 | 0.0 ± 0 |
| Cycle 1, Day 22 | 3.6 ± 6.1 | 2.4 ± 3.2 | -2.2 ± 5.8 | -1.0 ± 0 |
| Cycle 2, Day 1 | 6.1 ± 8.3 | 3.0 ± 2.9 | -0.2 ± 9.3 | 3.0 ± 0 |
| Cycle 2, Day 15 | 4.1 ± 6.3 | 2.5 ± 9.7 | -5.5 ± 3.4 | 16.0 ± 0 |
| Cycle 3 Day 1 | 6.2 ± 8.1 | 5.8 ± 10.0 | -4.0 ± 12.4 | 5.0 ± 0 |
| Cycle 3, Day 15 | 1.8 ± 10.5 | 2.0 ± 10.1 | -7.5 ± 7.0 | 8.0 ± 0 |
| Cycle 4, Day 1 | 5.5 ± 5.7 | 2.7 ± 6.8 | -0.4 ± 5.0 | 1.0 ± 0 |
| Cycle 5, Day 1 | 1.7 ± 6.1 | 5.0 ± 5.8 | -5.0 ± 4.5 | 1.0 ± 0 |
| Cycle 6, Day 1 | 5.9 ± 4.5 | 3.3 ± 11.1 | -2.0 ± 9.5 | 12.0 ± 0 |
| Cycle 7, Day 1 | 2.9 ± 4.8 | 4.5 ± 13.4 | -5.3 ± 9.0 | 30.0 ± 0 |
| Cycle 8, Day 1 | 7.8 ± 5.4 | 5.0 ± 7.1 | 0.5 ± 12.3 | 10.0 ± 0 |
| Cycle 9, Day 1 | 4.1 ± 8.4 | 4.0 ± 5.7 | -2.7 ± 1.5 | 4.0 ± 0 |
| Cycle 10, Day 1 | 3.7 ± 5.9 | 5.0 ± 0 | -2.3 ± 10.1 | 3.0 ± 0 |
| Cycle 11, Day 1 | 9.7 ± 14.1 | 10.0 ± 0 | 1.0 ± 7.1 | 24.0 ± 0 |
| Cycle 12, Day 1 | 9.8 ± 8.6 | 6.0 ± 0 | 2.0 ± 4.2 | 8.0 ± 0 |
| Cycle 13, Day 1 | 9.0 ± 7.6 | 4.0 ± 0 | 2.0 ± 0 | 10.0 ± 0 |
| Cycle 14, Day 1 | 5.6 ± 5.1 | 19.0 ± 0 | -9.0 ± 0 | 11.0 ± 0 |
| Cycle 15, Day 1 | 7.0 ± 8.0 | 10.0 ± 0 | -2.0 ± 0 | 7.0 ± 0 |
| Cycle 16, Day 1 | 9.8 ± 7.8 | 11.0 ± 0 | 7.0 ± 0 | 6.0 ± 0 |
| Cycle 17, Day 1 | 11.3 ± 3.5 | 11.0 ± 0 | 3.0 ± 0 | 7.0 ± 0 |
| Cycle 18, Day 1 | 5.0 ± 1.7 | — | -2.0 ± 0 | 3.0 ± 0 |
| Cycle 19, Day 1 | 4.0 ± 5.7 | — | 5.0 ± 0 | 8.0 ± 0 |
| Cycle 20, Day 1 | 12.5 ± 3.5 | — | -1.0 ± 0 | 2.0 ± 0 |
| Cycle 21, Day 1 | -3.0 ± 0 | — | — | 7.0 ± 0 |
| Cycle 22, Day 1 | 22.0 ± 0 | — | — | 8.0 ± 0 |
| Cycle 23, Day 1 | — | — | — | 7.0 ± 0 |
| Final visit | 5.8 ± 9.0 | 3.8 ± 14.0 | -2.0 ± 12.6 | 11.0 ± 0 |
The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction), 1=Symptomatic but completely ambulatory, 2=Symptomatic, \< 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, \> 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Only baseline data were collectable. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the planned end of study.
| Percentage of Participant | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Baseline 0 | 66.7 | 60.0 | 50.0 | 100.0 |
| Baseline 1 | 33.3 | 40.0 | 50.0 | 0 |
Participants with Concomitant Medications used from 28 days prior to screening until the final visit or end of study (EOS) were reported. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
| Percentage of Participants | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without SplenomegalyEdit | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Percentage of Participants With Concomitant Medications | 100 | 100 | 100 | 100 |
Cmax is the maximum observed concentration of drug in blood. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
Tmax is the time elapsed from the time of drug administration to maximum plasma concentration. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
CL is a measure of the body's elimination of a drug from plasma over time. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
CL/F is a measure of the body's elimination of a drug from plasma over time, after oral administration. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
Vdss/F is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the plasma. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
AUC (from zero to infinity) represents the total drug exposure over time. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
t1/2 is defined as the time required for the drug plasma concentration to be reduced to half. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
No measurements were reported for this outcome.
MPN-SAF Total Symptom Score is the sum of the following 10 items: early satiety, abdominal discomfort, inactivity, concentration issues, night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months and fatigue. The participant provides a severity score for each symptom on a scale of 0 as a minimum score (none/absent) to 10 (worst imaginable) as a maximum score. Baseline (Cycle 1, Day 1) MPN-SAF total symptom score and the mean change from baseline score at each timepoint are reported. The change from baseline score was calculated by subtracting the post-baseline score from the baseline score. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
| Score on a Scale | Ruxolitinib-Naïve Participants | Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| Baseline (Cycle 1 Day 1) | 31.95 ± 19.95 | 26.00 ± 11.83 |
| Cycle 2 Day 1 | -5.06 ± 12.91 | 0.80 ± 26.37 |
| Cycle 3 Day 28 | -6.38 ± 12.71 | -8.00 ± 15.08 |
| Cycle 5 Day 28, | -7.00 ± 12.72 | -9.50 ± 10.56 |
| Week 32 | -8.20 ± 12.79 | -5.00 ± 15.26 |
| Cycle 11 Day 28 | -4.60 ± 3.71 | -7.50 ± 3.54 |
| Cycle 14 Day 28 | -4.67 ± 5.54 | -10.50 ± 4.95 |
| Cycle 17 Day 28 | -3.25 ± 5.38 | -12.00 ± 1.41 |
| Cycle 20 Day 28 | -12.00 ± 0 | -8.00 ± 0 |
| Final Visit | -5.92 ± 9.96 | -7.20 ± 5.63 |
Reported EORTC QLQ-C30 Scores include: Cognitive function, Diarrhea Emotional functioning, Nausea and vomiting, Social functioning, Physical functioning, Global health status/QoL and Role functioning. The questions use a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores are averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The study was pre-maturely terminated by the sponsor's decision due to non-transformative efficacy and poor long-term tolerability of the dosing schedule as well as due to chronic gastrointestinal toxicity, therefore did not reach the end of study.
| Score on a Scale | Ruxolitinib-Naïve Participants | Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| EORTC QLQ-C30 Scores: Cognitive function Baseline | 65.83 ± 32.21 | 76.19 ± 30.21 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 2, Day 1 | 11.11 ± 11.43 | 8.33 ± 13.94 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 3 Day 28 | 7.02 ± 16.02 | 6.67 ± 19.00 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 5 Day 28 | 1.19 ± 22.13 | 11.11 ± 25.09 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 8 (Week 32) | 6.06 ± 18.67 | -3.33 ± 21.73 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 11 Day 28 | 8.33 ± 13.94 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 14 Day 28 | 5.56 ± 17.21 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 17 Day 28 | 0.00 ± 13.61 | -8.33 ± 11.79 |
| EORTC QLQ-C30 Scores: Cognitive function Cycle 20 Day 28 | 0 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Cognitive function Final Visit | 4.44 ± 18.33 | 6.67 ± 9.13 |
| EORTC QLQ-C30 Scores: Diarrhea Baseline | 8.33 ± 18.34 | 14.29 ± 17.82 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 2 Day 1 | -5.56 ± 17.15 | 5.56 ± 13.61 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 3 Day 28 | 1.75 ± 17.48 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 5 Day 28 | 7.14 ± 19.30 | 5.56 ± 13.61 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 8 (Week 32) | 9.09 ± 26.21 | 20.00 ± 18.26 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 11 Day 28 | 5.56 ± 13.61 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 14 Day 28 | 5.56 ± 13.61 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 17 Day 28 | 25.00 ± 31.91 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Diarrhea Cycle 20 Day 28 | 0 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Diarrhea Final visit | 13.33 ± 32.85 | 6.67 ± 14.91 |
| EORTC QLQ-C30 Scores: Emotional functioning Baseline | 65.83 ± 28.34 | 64.29 ± 21.36 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 1 Day 28 | 13.43 ± 20.24 | 15.28 ± 13.35 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 3 Day 28 | 14.04 ± 21.88 | 8.33 ± 10.21 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 5 Day 28 | 16.07 ± 20.53 | 6.94 ± 16.17 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 8 (Week 32) | 14.39 ± 18.29 | 5.00 ± 27.39 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 11 Day 28 | 6.94 ± 11.08 | 16.67 ± 0 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 14 Day 28 | 5.56 ± 10.09 | -4.17 ± 5.89 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 17 Day 28 | -8.33 ± 16.67 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Emotional functioning Cycle 20 Day 28 | 0 ± 0 | 8.33 ± 0 |
| EORTC QLQ-C30 Scores: Emotional functioning Final visit | 3.33 ± 18.31 | 16.67 ± 18.63 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Baseline | 10.00 ± 16.58 | 2.38 ± 6.30 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 2 Day 1 | -4.63 ± 12.53 | 8.33 ± 22.97 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 3 Day 28 | -1.75 ± 17.48 | 3.33 ± 13.94 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 5 Day 28 | -2.38 ± 11.05 | 8.33 ± 17.48 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 8 (Week 32) | 7.58 ± 23.99 | 16.67 ± 16.67 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 11 Day 28 | 2.78 ± 12.55 | 0.00 ± 23.57 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 14 Day 28 | -2.78 ± 6.80 | -8.33 ± 11.79 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Cycle 20 Day 28 | 0 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Nausea and vomiting Final visit | 11.11 ± 33.73 | 6.67 ± 19.00 |
| EORTC QLQ-C30 Scores: Social functioning Baseline | 67.50 ± 35.24 | 76.19 ± 13.11 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 2 Day 1 | 4.63 ± 12.53 | 0.00 ± 10.54 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 3 Day 28 | -1.75 ± 22.15 | 3.33 ± 13.94 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 5 Day 28 | 5.95 ± 24.98 | -2.78 ± 26.70 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 8 (Week 32) | 0.00 ± 18.26 | -6.67 ± 19.00 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 11 Day 28 | 0.00 ± 18.26 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 14 Day 28 | 0.00 ± 10.54 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 17 Day 28 | -4.17 ± 8.33 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Social functioning Cycle 20 Day 28 | 0 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Social functioning Final visit | 0.00 ± 30.86 | -6.67 ± 25.28 |
| EORTC QLQ-C30 Scores: Physical functioning Baseline | 86.33 ± 18.92 | 81.90 ± 11.36 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 2 Day 1 | 1.48 ± 9.02 | 2.22 ± 6.89 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 3 Day 28 | -2.81 ± 15.45 | 2.67 ± 5.96 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 5 Day 28 | 1.43 ± 16.16 | -2.22 ± 5.44 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 8 (Week 32) | 5.45 ± 15.72 | -4.00 ± 7.60 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 11 Day 28 | -1.11 ± 6.55 | -10.00 ± 14.14 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 14 Day 28 | -1.11 ± 2.72 | 0.00 ± 9.43 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 17 Day 28 | 1.67 ± 3.33 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Physical functioning Cycle 20 Day 28 | 0 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Physical functioning Final visit | -4.44 ± 9.65 | -2.67 ± 7.60 |
| EORTC QLQ-C30 Scores: Global health status/QoL Baseline | 61.25 ± 20.28 | 60.71 ± 7.93 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 2 Day 1 | 2.31 ± 18.92 | 1.39 ± 8.19 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 3 Day 28 | 7.89 ± 14.56 | 11.67 ± 9.50 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 5 Day 28 | 7.14 ± 19.84 | 0.00 ± 17.48 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 8 (Week 32) | 9.09 ± 23.41 | -8.33 ± 13.18 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 11 Day 28 | 1.39 ± 23.81 | 8.33 ± 11.79 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 14 Day 28 | 2.78 ± 21.52 | 8.33 ± 0 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 17 Day 28 | 10.42 ± 20.83 | 16.67 ± 0 |
| EORTC QLQ-C30 Scores: Global health status/QoL Cycle 20 Day 28 | 25.00 ± 0 | 25.00 ± 0 |
| EORTC QLQ-C30 Scores: Global health status/QoL Final visit | -3.33 ± 23.32 | 13.33 ± 17.28 |
| EORTC QLQ-C30 Scores: Role functioning Baseline | 74.17 ± 28.85 | 76.19 ± 16.27 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 2 Day 1 | 7.41 ± 17.36 | -8.33 ± 17.48 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 3 Day 28 | 2.63 ± 17.80 | 0.00 ± 11.79 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 5 Day 28 | 7.14 ± 15.63 | -2.78 ± 22.15 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 8 (Week 32) | 15.15 ± 21.67 | 0.00 ± 20.41 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 11 Day 28 | -2.78 ± 19.48 | -8.33 ± 11.79 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 14 Day 28 | 5.56 ± 8.61 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 17 Day 28 | 8.33 ± 9.62 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Role functioning Cycle 20 Day 28 | 16.67 ± 0 | 0 ± 0 |
| EORTC QLQ-C30 Scores: Role functioning Final Visit | -13.33 ± 32.24 | 6.67 ± 9.13 |
The PGIC is a one-item measure used to assess perceived treatment benefit. Participants were asked "Since the start of the treatment you've received in this study, your polycythemia vera (PV) symptoms are: 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse'. The study was pre-maturely terminated by the sponsor's decision, therefore did not reach the end of study.
| Count of Participants | Ruxolitinib-Naïve Participants | Ruxolitinib-Resistant or Intolerant Participants |
|---|---|---|
| Cycle 2, Day 1 Very Much Improved | 0 | 0 |
| Cycle 2, Day 1 Much Improved | 4 | 1 |
| Cycle 2, Day 1 Minimally Improved | 5 | 3 |
| Cycle 2, Day 1 No Change | 6 | 1 |
| Cycle 2, Day 1 Minimally Worse | 1 | 1 |
| Cycle 2, Day 1 Much Worse | 0 | 0 |
| Cycle 2, Day 1 Very Much Worse | 0 | 0 |
| Cycle 2, Day 1 Not Assessed | 0 | 1 |
| Cycle 3 Day 28 Very Much Improved | 4 | 1 |
| Cycle 3 Day 28 Much Improved | 4 | 1 |
| Cycle 3 Day 28 Minimally Improved | 6 | 3 |
| Cycle 3 Day 28 No Change | 3 | 0 |
| Cycle 3 Day 28 Minimally Worse | 0 | 0 |
| Cycle 3 Day 28 Much Worse | 0 | 0 |
| Cycle 3 Day 28 Very Much Worse | 0 | 0 |
| Cycle 3 Day 28 Not Assessed | 0 | 1 |
| Cycle 5 Day 28 Very Much Improved | 2 | 1 |
| Cycle 5 Day 28 Much Improved | 6 | 1 |
| Cycle 5 Day 28 Minimally Improved | 2 | 4 |
| Cycle 5 Day 28 No Change | 1 | 0 |
| Cycle 5 Day 28 Minimally Worse | 0 | 0 |
| Cycle 5 Day 28 Much Worse | 0 | 0 |
| Cycle 5 Day 28 Very Much Worse | 0 | 0 |
| Cycle 5 Day 28 Not Assessed | 4 | 0 |
| Week 32 Very Much Improved | 3 | 0 |
| Week 32 Much Improved | 3 | 1 |
| Week 32 Minimally Improved | 3 | 3 |
| Week 32 No Change | 1 | 1 |
| Week 32 Minimally Worse | 1 | 0 |
| Week 32 Much Worse | 0 | 0 |
| Week 32 Very Much Worse | 0 | 0 |
| Week 32 Not Assessed | 0 | 0 |
| Cycle 11 Day 28 Very Much Improved | 1 | 0 |
| Cycle 11 Day 28 Much Improved | 3 | 2 |
| Cycle 11 Day 28 Minimally Improved | 0 | 0 |
| Cycle 11 Day 28 No Change | 0 | 0 |
| Cycle 11 Day 28 Minimally Worse | 1 | 0 |
| Cycle 11 Day 28 Much Worse | 0 | 0 |
| Cycle 11 Day 28 Very Much Worse | 0 | 0 |
| Cycle 11 Day 28 Not Assessed | 0 | 0 |
| Cycle 14 Day 28 Very Much Improved | 2 | 0 |
| Cycle 14 Day 28 Much Improved | 2 | 2 |
| Cycle 14 Day 28 Minimally Improved | 0 | 0 |
| Cycle 14 Day 28 No change | 1 | 0 |
| Cycle 14 Day 28 Minimally Worse | 1 | 0 |
| Cycle 14 Day 28 Much Worse | 0 | 0 |
| Cycle 14 Day 28 Very Much Worse | 0 | 0 |
| Cycle 14 Day 28 Not Assessed | 0 | 0 |
| Cycle 17 Day 28 Very Much Improved | 1 | 0 |
| Cycle 17 Day 28 Much Improved | 1 | 2 |
| Cycle 17 Day 28 Minimally Improved | 1 | 0 |
| Cycle 17 Day 28 No Change | 1 | 0 |
| Cycle 17 Day 28 Minimally Worse | 0 | 0 |
| Cycle 17 Day 28 Much Worse | 0 | 0 |
| Cycle 17 Day 28 Very Much Worse | 0 | 0 |
| Cycle 17 Day 28 Not Assessed | 0 | 0 |
| Cycle 20 Day 28 Very Much Improved | 0 | 0 |
| Cycle 20 Day 28 Much Improved | 0 | 0 |
| Cycle 20 Day 28 Minimally Improved | 1 | 0 |
| Cycle 20 Day 28 No Change | 0 | 0 |
| Cycle 20 Day 28 Minimally Worse | 0 | 0 |
| Cycle 20 Day 28 Much Worse | 0 | 0 |
| Cycle 20 Day 28 Very Much Worse | 0 | 0 |
| Cycle 20 Day 28 Not Assessed | 0 | 0 |
| Final Visit Very Much Improved | 3 | 1 |
| Final Visit Much Improved | 3 | 3 |
| Final Visit Minimally Improved | 2 | 1 |
| Final Visit No Change | 6 | 0 |
| Final Visit Minimally Worse | 1 | 0 |
| Final Visit Much Worse | 0 | 0 |
| Final Visit Very Much Worse | 0 | 0 |
| Final Visit Not Assessed | 2 | 0 |
Collected over From Baseline to end of study (up to 2 years) post initial dose or until subject discontinued. Safety follow-up: Until 28 days after the last dose of study treatment or until initiating another anti-cancer therapy.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib Naive-With Splenomegaly | 0/15 (0%) | 2/15 (13.3%) | 15/15 (100%) |
| Ruxolitinib Naive-Without Splenomegaly | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Ruxolitinib Naive-With Splenomegaly | Ruxolitinib Naive-Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/15 | 1/5 | 0/6 | 0/1 |
| Atrial fibrillationCardiac disorders | 1/15 | 0/5 | 0/6 | 0/1 |
| Atrial flutterCardiac disorders | 1/15 | 0/5 | 0/6 | 0/1 |
| Event | Ruxolitinib Naive-With Splenomegaly | Ruxolitinib Naive-Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly |
|---|---|---|---|---|
| Dry eyeEye disorders | 1/15 | 0/5 | 1/6 | 1/1 |
| ConstipationGastrointestinal disorders | 5/15 | 0/5 | 3/6 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 11/15 | 3/5 | 6/6 | 1/1 |
| NauseaGastrointestinal disorders | 13/15 | 5/5 | 6/6 | 1/1 |
| VomitingGastrointestinal disorders | 6/15 | 3/5 | 1/6 | 1/1 |
| FatigueGeneral disorders | 5/15 | 0/5 | 4/6 | 1/1 |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 1/5 | 1/6 | 1/1 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 0/5 | 1/6 | 1/1 |
| HeadacheNervous system disorders | 3/15 | 1/5 | 3/6 | 1/1 |
| Taste disorderNervous system disorders | 5/15 | 0/5 | 0/6 | 1/1 |
| Age, Continuous(Years) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | Total |
|---|---|---|---|---|---|
| Mean | 54.5 ± 10.7 | 56.8 ± 8.8 | 60.3 ± 8.4 | 55 ± 0 | 56.3 ± 9.6 |
| Sex: Female, Male(Participants) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | Total |
|---|---|---|---|---|---|
| Female | 2 | 5 | 4 | 0 | 11 |
| Male | 13 | 0 | 2 | 1 | 16 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 14 | 5 | 6 | 1 | 26 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib-naïve Participants With Splenomegaly | Ruxolitinib-naïve Participants Without Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly | Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 0 | 1 |
| White | 14 | 5 | 6 | 1 | 26 |
Documents are hosted by the registry — open the source record to download them.
This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche